Ipsen/Galderma's esthetic use botox Azzalure cleared in 15 EU countries

French drugmaker Ipsen and specialty drug group Galderma, which is co-owned by L'Oreal and Nestle, say that Azzalure, their co-marketed  botulinum A toxin muscle relaxant specifically developed for esthetic  use, has received the collective green light from 15 European countries'  health authorities for national marketing authorizations. The decision  was based on clinical trials involving more than 2,600 patients, which  confirmed the safety and efficacy of Azzalure. Ipsen signed an accord  involving its botox product with Galderma two years ago (Marketletter  March 5, 2007). Under the terms of the deal, Ipsen granted Galderma  exclusive rights to develop and market a specific formulation of the  drug in the European Union, Russia and certain territories in the  Middle East and eastern Europe, in return for 10.0 million euros ($13.2  million) up front and up to 20.0 million euros in development-based  milestones and royalties on product sales.